Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

MEA UTI Drugs Companies

ID: MRFR/Pharma/1900-HCR
84 Pages
Vikita Thakur
Last Updated: February 16, 2025
MEA Urinary Tract Infection (UTI) drugs companies play a pivotal role in addressing the prevalent health issue of UTIs in the Middle East and Africa region. These pharmaceutical firms focus on researching, developing, and manufacturing medications to combat bacterial infections affecting the urinary system. Leveraging advanced technologies, these companies strive to offer innovative and effective antibiotics, targeting various strains of bacteria responsible for UTIs.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

MEA UTI Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.2%
2024 Market Size$ 0.28 Billion
2025 Market Size$ 0.29 Billion
2035 Market Size$ 0.4 Billion
Key Players
Bristol-Myers Squibb
AstraZeneca
Pfizer
Novartis
Sanofi
GSK
Trends
  • Rising Incidence of UTIs
  • Advancements in Treatment Options
  • Focus on Preventive Healthcare
Opportunities
  • Increasing Healthcare Expenditure
  • Rising Awareness of UTI Management
  • Government Initiatives and Policies
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the MEA UTI Drugs Market

MEA Urinary Tract Infection Drugs Key Companies
 
Latest MEA Urinary Tract Infection Drugs Companies Update

Pfizer Launched Zylacef® (ceftoceftam) in several MEA countries, a new generation cephalosporin antibiotic effective against a broad spectrum of bacteria causing UTIs.

Teva Pharmaceutical Industries Received approval for Factive® (levofloxacin) in multiple MEA markets, expanding its reach for this fluoroquinolone antibiotic commonly used for UTIs.

AstraZeneca Introduced Recarb (lefamulin) in some MEA countries, offering a novel antibiotic option for complicated UTIs caused by multidrug-resistant bacteria.

GlaxoSmithKline (GSK) Expanding its reach in the MEA UTI market by launching awareness campaigns and collaborating with local healthcare providers to improve antibiotic stewardship practices.

Merck & Co. Partnered with non-profit organizations in the MEA region to provide educational resources and access to UTI diagnostics and treatment for underserved communities.

Novartis International AG Joined forces with local research institutions in the MEA region to investigate antibiotic resistance patterns and develop effective UTI treatment strategies for the region.

List of MEA Urinary Tract Infection Drugs Key Companies in the Market

  • Bayer AG
  • Novartis AG
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd
  • AstraZeneca
  • Cipla Inc.
  • Reddy’s Laboratories Ltd

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035